



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peschke et al.

Application No.: 09/356,313

Group Art Unit: 1653

Filed: July 16, 1999

Examiner: D. Lukton

Confirmation No: 7669

For: Compounds With Growth Hormone Releasing Properties

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED

AUG 26 2003

TECH CENTER 1600/2900

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S/ is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on August 30, 1999 (reel 010209, frame 0370)).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

Any patent granted on application serial no. 09/337,809

Is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only or and during such period that the legal title to said patent shall be the same as the legal title to

Any patent granted on application serial no. 09/337,809

This agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of


any patent granted on application serial no. 09/356,313

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully submitted,

Dated:

9/12/03

A handwritten signature in dark ink, appearing to read 'Reza Green', is written over a horizontal line.

Reza Green, Reg. No. 38,475  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, N.J. 08540  
(609) 919-7800